Shares of Graybug Vision, Inc. (NASDAQ:GRAY – Get Free Report) were down 5.7% during trading on Thursday . The company traded as low as $4.13 and last traded at $4.16. Approximately 17,449 shares traded hands during mid-day trading, an increase of 706% from the average daily volume of 2,165 shares. The stock had previously closed at $4.41.
Graybug Vision Price Performance
The company has a fifty day moving average price of $4.44 and a 200 day moving average price of $4.65. The company has a market capitalization of $6.54 million, a P/E ratio of -0.17 and a beta of 1.20.
Graybug Vision Company Profile
Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.
Featured Articles
- Five stocks we like better than Graybug Vision
- What is MarketRank™? How to Use it
- 3 Leveraged ETFs to Multiply Returns
- Election Stocks: How Elections Affect the Stock Market
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- Stock Analyst Ratings and Canadian Analyst Ratings
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.
